NO20080141L - Indanderivater som modulatorer av ionekanaler - Google Patents
Indanderivater som modulatorer av ionekanalerInfo
- Publication number
- NO20080141L NO20080141L NO20080141A NO20080141A NO20080141L NO 20080141 L NO20080141 L NO 20080141L NO 20080141 A NO20080141 A NO 20080141A NO 20080141 A NO20080141 A NO 20080141A NO 20080141 L NO20080141 L NO 20080141L
- Authority
- NO
- Norway
- Prior art keywords
- ion channels
- modulators
- indane derivatives
- indane
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/47—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68891905P | 2005-06-09 | 2005-06-09 | |
| PCT/US2006/022818 WO2006133459A1 (en) | 2005-06-09 | 2006-06-09 | Indane derivatives as modulators of ion channels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20080141L true NO20080141L (no) | 2008-01-09 |
Family
ID=37000013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20080141A NO20080141L (no) | 2005-06-09 | 2008-01-09 | Indanderivater som modulatorer av ionekanaler |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7605174B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1888547A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2008543785A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080019693A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101238109B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006254809B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2611731A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL187997A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007015726A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20080141L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ564374A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2007148504A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006133459A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200800191B (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| EP1891063B1 (en) * | 2005-05-10 | 2012-07-25 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
| KR20080021030A (ko) * | 2005-05-16 | 2008-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 바이사이클릭 유도체 |
| CA2622076A1 (en) * | 2005-09-09 | 2007-03-15 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of voltage gated ion channels |
| RU2008113209A (ru) | 2005-10-06 | 2009-10-10 | Санофи-Авентис (Fr) | Бициклические {1, 3, 4}тиадиазол-2-иламиды арилсульфоновой кислоты, способы их получения и их использование в качестве фармацевтических средств |
| JP2009512717A (ja) * | 2005-10-21 | 2009-03-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルを調節するための誘導体 |
| TW200740803A (en) * | 2005-12-21 | 2007-11-01 | Vertex Pharma | Heterocyclic derivatives as modulators of ion channels |
| CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| MX2010005307A (es) * | 2007-11-13 | 2010-07-28 | Vertex Pharma | Derivados heterociclicos como moduladores de canales de iones. |
| JP2011503112A (ja) * | 2007-11-13 | 2011-01-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の処置のためのイオンチャンネルのモジュレーターとしての4(−3−(−2−(フェニル)モルホリノ)−2−オキソピロリジン−1−イル)−n−(チアゾール−2−イル)ベンゼンスルホンアミド誘導体および関連化合物 |
| US20110031892A1 (en) * | 2008-04-30 | 2011-02-10 | Sharp Kabushiki Kaisha | Lighting device and display device |
| WO2010002956A2 (en) * | 2008-07-01 | 2010-01-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| CA2732757A1 (en) * | 2008-08-06 | 2010-02-11 | Merck Sharp & Dohme Corp. | Substituted dihydroisoquinolinone and isoquinolinedione derivatives as calcium channel blockers |
| JP2014532660A (ja) * | 2011-10-28 | 2014-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 電位作動型ナトリウムチャネルにおける選択活性を有するベンゾオキサゾリノン化合物 |
| AU2013332648B2 (en) | 2012-10-15 | 2017-09-07 | In Therapeutics | Sodium channel blockers, preparation method thereof and use thereof |
| AR094667A1 (es) | 2013-01-31 | 2015-08-19 | Vertex Pharma | Piridonamidas como moduladores de canales de sodio |
| MX389003B (es) | 2016-05-19 | 2025-03-20 | Tabula Rasa Healthcare Inc | Métodos de tratamiento que tienen toxicidad relacionada con fármacos reducida y métodos para identificar la probabilidad de daño que surja de medicamentos recetados a pacientes. |
| CA3105657A1 (en) | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting nav1.8 |
| CN112689629B (zh) | 2018-07-09 | 2024-04-23 | 利伯研究所公司 | 用于抑制Nav1.8的哒嗪化合物 |
| US20220162169A1 (en) * | 2019-02-20 | 2022-05-26 | Jiangsu Hengrui Medicine Co., Ltd. | 6-oxo-1,6-dihydropyridazine prodrug derivative, preparation method therefor, and application thereof in medicine |
| EP4334298A1 (en) | 2021-06-14 | 2024-03-13 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
| CN116041230B (zh) * | 2023-01-08 | 2024-03-19 | 中国海洋大学 | 一种nlrp3炎症小体抑制剂及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| GB9800750D0 (en) * | 1998-01-14 | 1998-03-11 | Lilly Co Eli | Pharmaceutical compound |
| TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| CA2539227A1 (en) * | 2003-08-08 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
-
2006
- 2006-06-09 MX MX2007015726A patent/MX2007015726A/es active IP Right Grant
- 2006-06-09 KR KR1020087000464A patent/KR20080019693A/ko not_active Withdrawn
- 2006-06-09 RU RU2007148504/04A patent/RU2007148504A/ru not_active Application Discontinuation
- 2006-06-09 CA CA002611731A patent/CA2611731A1/en not_active Abandoned
- 2006-06-09 EP EP06772925A patent/EP1888547A1/en not_active Withdrawn
- 2006-06-09 CN CN2006800287819A patent/CN101238109B/zh not_active Expired - Fee Related
- 2006-06-09 NZ NZ564374A patent/NZ564374A/en not_active IP Right Cessation
- 2006-06-09 WO PCT/US2006/022818 patent/WO2006133459A1/en not_active Ceased
- 2006-06-09 AU AU2006254809A patent/AU2006254809B2/en not_active Ceased
- 2006-06-09 JP JP2008516024A patent/JP2008543785A/ja not_active Ceased
- 2006-06-09 US US11/450,695 patent/US7605174B2/en active Active
- 2006-06-09 ZA ZA200800191A patent/ZA200800191B/xx unknown
-
2007
- 2007-12-09 IL IL187997A patent/IL187997A0/en unknown
-
2008
- 2008-01-09 NO NO20080141A patent/NO20080141L/no not_active Application Discontinuation
-
2009
- 2009-08-31 US US12/550,649 patent/US7989481B2/en active Active
-
2012
- 2012-03-29 JP JP2012076707A patent/JP2012126745A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NZ564374A (en) | 2010-11-26 |
| AU2006254809B2 (en) | 2012-03-15 |
| IL187997A0 (en) | 2008-03-20 |
| JP2012126745A (ja) | 2012-07-05 |
| KR20080019693A (ko) | 2008-03-04 |
| CN101238109A (zh) | 2008-08-06 |
| WO2006133459A1 (en) | 2006-12-14 |
| AU2006254809A1 (en) | 2006-12-14 |
| MX2007015726A (es) | 2008-03-04 |
| CN101238109B (zh) | 2011-12-14 |
| RU2007148504A (ru) | 2009-06-27 |
| US20070117801A1 (en) | 2007-05-24 |
| JP2008543785A (ja) | 2008-12-04 |
| US7989481B2 (en) | 2011-08-02 |
| US20090326023A1 (en) | 2009-12-31 |
| HK1119433A1 (en) | 2009-03-06 |
| EP1888547A1 (en) | 2008-02-20 |
| CA2611731A1 (en) | 2006-12-14 |
| US7605174B2 (en) | 2009-10-20 |
| ZA200800191B (en) | 2009-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20080141L (no) | Indanderivater som modulatorer av ionekanaler | |
| NO20076447L (no) | Bicykliske derivater som modulatorer av ionekanaler | |
| NO20083220L (no) | Heterocykliske derivater som modulatorer for ionekanaler | |
| NO20090157L (no) | Tienpyrimidiner anvendelige som modulatorer av ionekanaler | |
| NO20071742L (no) | Kinazoliner som er nyttige som modulatorer av ionekanaler | |
| NO20054546L (no) | Kinazoliner anvendelige som modulatorer av ionekanaler | |
| NO20060518L (no) | Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler | |
| MX2010003009A (es) | Piridil sulfonamidas como moduladores de canales ionicos. | |
| NO20084435L (no) | C-MET proteinkinaseinhibitorer | |
| NO20064852L (no) | Azaindoler som er nyttige som inhibitorer av jak og andre proteinkinaser | |
| WO2010002956A3 (en) | Heterocyclic derivatives as modulators of ion channels | |
| NO20084652L (no) | Deazapuriner anvendelige som inhibitorer av januskinaser | |
| NO20072567L (no) | Triazoler nyttige som proteinkinase-inhibitorer | |
| NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
| MX2010003865A (es) | Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| MX2010003864A (es) | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| NO20082746L (no) | Kinazoliner anvendelige som modulatorer for spenningsstyrte ionekanaler | |
| NO20065727L (no) | Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter | |
| NO20052888L (no) | Diamintriazoler anvendelige som inhibitorer av proteinkinaser | |
| NO20074431L (no) | Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer | |
| AU2008321142A8 (en) | Heterocyclic derivatives as modulators of ion channels | |
| MX2010005309A (es) | Derivados de 4-(3-(2-(fenil)morfolino)-2-oxopirrolidin-1-il-n-(tia zol-2-il)bencensulfonamida y compuestos relacionados como moduladores de canales ionicos para el tratamiento del dolor. | |
| NO20076186L (no) | Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav | |
| MX2010003563A (es) | Inhibidores de proteina cinasa de c-met. | |
| NO20076191L (no) | Magnesiumsalter av HMG-COA reduktaseinhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |